We are live on ! Find out more
ACA

Acorn Capital Advisors Portfolio holdings

AUM $352M
1-Year Est. Return 299.18%
This Fund
S&P 500
This Quarter Est. Return
+20.59%
1 Year Est. Return
+299.18%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$352M
AUM Growth
+$56.7M
Cap. Flow
+$20.9M
Cap. Flow %
5.94%
Top 10 Hldgs %
88.87%
Holding
23
New
2
Increased
4
Reduced
6
Closed
1

Top Buys

Rank Stock Value
1
JBIO
Jade Biosciences
JBIO
+$11.4M
2
CADL icon
Candel Therapeutics
CADL
+$4.99M
3
URGN icon
UroGen Pharma
URGN
+$4.51M
4
KPTI icon
Karyopharm Therapeutics
KPTI
+$2.19M
5
LONA
LeonaBio Inc
LONA
+$864K

Top Sells

Rank Stock Value
1
ACRV icon
Acrivon Therapeutics
ACRV
+$977K
2
QTTB icon
Q32 Bio
QTTB
+$847K
3
JSPR icon
Jasper Therapeutics
JSPR
+$521K
4
CRDF icon
Cardiff Oncology
CRDF
+$411K
5
HELP
Cybin Inc
HELP
+$212K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TERN
1
DELISTED
Terns Pharmaceuticals
TERN
$92.1M 26.17%
1,746,264
– –
CGON icon
2
CG Oncology
CGON
$6.28B
$76.6M 21.77%
1,130,501
-1,000
-0.1% -$56.7K
URGN icon
3
UroGen Pharma
URGN
$1.86B
$30.1M 8.55%
1,673,420
+225,000
+16% +$4.51M
PBYI icon
4
Puma Biotechnology
PBYI
$404M
$26.4M 7.5%
4,131,299
– –
TRVI icon
5
Trevi Therapeutics
TRVI
$2.59B
$25.6M 7.27%
2,144,844
– –
CADL icon
6
Candel Therapeutics
CADL
$733M
$17.2M 4.89%
3,497,948
+917,431
+36% +$4.99M
BCAX
7
Bicara Therapeutics
BCAX
$1.78B
$12.8M 3.64%
643,382
– –
OKUR
8
OnKure Therapeutics
OKUR
$154M
$11.8M 3.34%
2,839,674
– –
JBIO
9
Jade Biosciences
JBIO
$1.2B
$11.1M 3.14%
+786,760
New +$11.4M
TARA icon
10
Protara Therapeutics
TARA
$220M
$9.13M 2.59%
1,752,115
– –
VSTM icon
11
Verastem
VSTM
$510M
$7.79M 2.21%
1,469,153
– –
HELP
12
Cybin Inc
HELP
$485M
$7.39M 2.1%
1,540,266
-32,757
-2% -$212K
LONA
13
LeonaBio Inc
LONA
$66.3M
$6.52M 1.85%
634,539
+132,800
+26% +$864K
AURA icon
14
Aura Biosciences
AURA
$725M
$3.99M 1.13%
595,744
– –
WHWK
15
Whitehawk Therapeutics
WHWK
$190M
$3.93M 1.12%
1,139,363
– –
CRDF icon
16
Cardiff Oncology
CRDF
$66.5M
$2.85M 0.81%
1,762,084
-200,000
-10% -$411K
QTTB icon
17
Q32 Bio
QTTB
$466M
$2.02M 0.57%
315,052
-178,373
-36% -$847K
KPTI icon
18
Karyopharm Therapeutics
KPTI
$43.5M
$1.6M 0.46%
+287,826
New +$2.19M
JSPR icon
19
Jasper Therapeutics
JSPR
$21M
$1.24M 0.35%
1,411,492
-375,000
-21% -$521K
XFOR icon
20
X4 Pharmaceuticals
XFOR
$375M
$967K 0.27%
234,039
-39,310
-14% -$147K
BCAB icon
21
BioAtla
BCAB
$5.46M
$865K 0.25%
108,127
+11,425
+12% +$134K
YARW
22
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
$855 ﹤0.01%
29
– –
ACRV icon
23
Acrivon Therapeutics
ACRV
$64.2M
– –
-405,237
Closed -$977K

Similar funds

PIC
PCJ Investment Counsel Toronto, Ontario, Canada $352M AUM 68.32% 1-Year Est. Return
HIA
HTG Investment Advisors New Canaan, Connecticut $352M AUM 17.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
EC
Elmind Capital New York $352M AUM
AW
Alaethes Wealth Glenbrook, Nevada $351M AUM 22.79% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
FWM
ForthRight Wealth Management Alpharetta, Georgia $353M AUM 12.98% 1-Year Est. Return
BL
BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return

Acorn Capital Advisors's Q1 2026 Portfolio in Review

As of Q1 2026, Acorn Capital Advisors held 23 positions worth $352M, up 19% from $295M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Acorn Capital Advisors deployed $20.9M of net new capital in Q1 2026, opening 2 new positions and adding to 4 existing holdings. Its largest new stake was Jade Biosciences: 786,760 shares worth $11.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Q32 Bio, an estimated $847K trimmed.

  • Acorn Capital Advisors's largest Q1 2026 buy was Jade Biosciences: 786,760 shares worth $11.1M.
  • Acorn Capital Advisors added most to Candel Therapeutics in Q1 2026, an estimated $4.99M increase.
  • Acorn Capital Advisors's biggest Q1 2026 reduction was Q32 Bio, cutting an estimated $847K.
  • Acorn Capital Advisors fully exited Acrivon Therapeutics in Q1 2026, selling an estimated $977K.
  • Acorn Capital Advisors's ten largest holdings make up 89% of its $352M portfolio in Q1 2026.
  • Acorn Capital Advisors opened 2 new positions and closed 1 in Q1 2026.
  • Acorn Capital Advisors's portfolio value rose 19% quarter-over-quarter to $352M.

Based on Acorn Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.